A Revolution Medicines drug helped pancreatic cancer patients live nearly six months longer compared to those treated with standard of care chemotherapy, meeting the goals of a pivotal study in this ...
Revolution Medicines’ pan-RAS inhibitor helped patients with a highly aggressive form of pancreatic cancer live an average of six months longer than chemotherapy, hitting a goal of the phase 3 study.
Chairman of the Higher Education Commission (HEC) Dr Niaz Ahmed visited the Lahore Chamber of Commerce and Industry (LCCI) and met with President Faheemur Rehman Saigol to discuss strengthening the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results